ADC Therapeutics (ADCT) EPS (Weighted Average and Diluted): 2020-2022
Historic EPS (Weighted Average and Diluted) for ADC Therapeutics (ADCT) over the last 3 years, with Dec 2022 value amounting to -$1.99.
- ADC Therapeutics' EPS (Weighted Average and Diluted) fell 187.69% to -$0.57 in Q3 2023 from the same period last year, while for Sep 2023 it was -$0.73, marking a year-over-year decrease of 157.94%. This contributed to the annual value of -$1.99 for FY2022, which is 33.67% up from last year.
- ADC Therapeutics' EPS (Weighted Average and Diluted) amounted to -$1.99 in FY2022, which was up 33.67% from -$3 recorded in FY2021.
- Over the past 5 years, ADC Therapeutics' EPS (Weighted Average and Diluted) peaked at -$1.99 during FY2022, and registered a low of -$3.77 during FY2020.
- Its 3-year average for EPS (Weighted Average and Diluted) is -$2.92, with a median of -$3 in 2021.
- Data for ADC Therapeutics' EPS (Weighted Average and Diluted) shows a peak YoY soared of 33.67% (in 2022) over the last 5 years.
- Yearly analysis of 3 years shows ADC Therapeutics' EPS (Weighted Average and Diluted) stood at -$3.77 in 2020, then grew by 20.42% to -$3 in 2021, then surged by 33.67% to -$1.99 in 2022.